| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5882810 | Clinical Lymphoma Myeloma and Leukemia | 2016 | 11 Pages |
Abstract
Overall, results from the ENRICH study demonstrated that switching to nilotinib can mitigate imatinib-related chronic low-grade nonhematologic AEs in patients with chronic myeloid leukemia in chronic phase, in conjunction with acceptable safety and achievement of molecular responses. This trial was registered at www.clinicaltrials.gov as NCT00980018.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Jorge E. Cortes, Jeffrey H. Lipton, Carole B. Miller, Lambert Busque, Luke P. Akard, Javier Pinilla-Ibarz, Christopher Keir, Ghulam Warsi, Felice P. Lin, Michael J. Mauro,